April « 2022 « Dr. Blackwell's BLOG

Tuesday, April 12, 2022

Dr. Blackwell to Present at 2022 National Conference of the American Association of Nurse Practitioners

Filed under: Nursing Science — Dr. Christopher Blackwell @ 19:13

Dr. Blackwell will be giving 3 presentations at the 2022 American Association of Nurse Practitioners (AANP) National Conference in Orlando, Florida in June. These presentations include Preventing HIV in 2022: Integrating Evidence into Practice (6/22: Session 22.2.036), Advanced Practice Care of Patients with HIV and AIDS (6/23: Session 22.3.025), and Evidence-Based Care of LGBTQ Adolescents (6/22: Session 22.2.155). Attendees should plan to register for these sessions during the conference if they’d like to attend. The Preventing HIV in 2022: Integrating Evidence into Practice (Session 22.2.036) and Evidence-Based Care of LGBTQ Adolescents (Session 22.2.155) presentations will also be given at the 2022 AANP National Virtual Conference. Follow the link below to register for the 2022 National AANP Conference:

https://www.aanp.org/events/2022-aanp-national-conference

Comments (0)

Friday, April 1, 2022

Dr. Blackwell’s Work to be Published in the Journal of the American Association of Nurse Practitioners

Filed under: Nursing Science — Dr. Christopher Blackwell @ 11:38

Dr. Blackwell’s original article, “Monthly Injectable Cabotegravir/Rilpivirine to Manage HIV Infection in Adults” has undergone the rigorous peer review process and has been accepted for publication in the Journal of the American Association of Nurse Practitioners, considered the premier journal of the NP profession. Written with collaborator Dr. Humberto Lopez-Castillo, the article examines the use of a new approach to managing HIV infection in adults using injectable antiretrovirals. The article will appear in a forthcoming issue of the journal. The abstract appears below:

The FDA recently approved a unique treatment regimen for management of HIV type-1 infection in adults. A one-time per month injection of cabotegravir/rilpivirine can replace a current, stable antiretroviral regimen in those with virological suppression, without history of treatment failure or known or suspected resistance with cabotegravir or rilpivrine. A one-month oral trial should be initiated prior to switching to the extended-release injectable formulation. Cabotegravir/rilpivirine showed continued virologic suppression without clinically relevant changes in CD4+ cell counts. Clinicians should understand this new HIV regimen, its indications and suitability for select patients, administration and dosing, interactions, and most reported adverse events.

Comments (0)